Jury Says Roche's Mircera Infringed Amgen Patents
In its verdict, the jury in the U.S. District Court for the District of Massachusetts found that Mircera had literally infringed nine of Amgen's patent claims and had infringed another claim under the doctrine of equivalents. The jury also found that all of Amgen's patent claims were valid.
“We're thrilled with it,” said Bill Gaede, a partner with McDermott Will & Emery...
To view the full article, register now.